LEXICON PHARMACEUTICALS, INC. Cash and Restricted Cash
LEXICON PHARMACEUTICALS, INC. (LXRX) had Cash and Restricted Cash of $40.92 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-06
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $40.92M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $67.09M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $63.33M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $78.66M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $40.92M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $67.09M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $63.33M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $78.66M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $50.36M 10-Q · filed 2026-08-06 |
| 2025-03-31 | $62.89M 10-Q · filed 2026-05-07 |
| 2024-12-31 | $66.66M 10-Q · filed 2026-08-06 |
| 2024-09-30 | $34.55M 10-Q · filed 2025-11-06 |
| 2024-06-30 | $35.62M 10-Q · filed 2025-08-06 |
| 2024-03-31 | $96.49M 10-Q · filed 2025-05-14 |
| 2023-12-31 | $22.46M 10-K · filed 2026-03-05 |
| 2023-09-30 | $21.12M 10-Q · filed 2024-11-13 |
| 2023-06-30 | $102.27M 10-Q · filed 2024-08-02 |
| 2023-03-31 | $26.00M 10-Q · filed 2024-05-02 |
| 2022-12-31 | $46.34M 10-K · filed 2026-03-05 |
| 2022-09-30 | $18.83M 10-Q · filed 2023-11-08 |
| 2022-06-30 | $21.45M 10-Q · filed 2023-08-04 |
| 2021-12-31 | $64.06M 10-K · filed 2025-03-07 |
| 2020-12-31 | $126.26M 10-K · filed 2024-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |